Document Detail

Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies?
MedLine Citation:
PMID:  23603458     Owner:  NLM     Status:  Publisher    
Epigenetic alterations represent a key cancer hallmark, even in hematologic malignancies (HMs) or blood cancers, whose clinical features display a high inter-individual variability. Evidence accumulated in recent years indicates that inactivating DNA hypermethylation preferentially targets the subset of polycomb group (PcG) genes that are regulators of developmental processes. Conversely, activating DNA hypomethylation targets oncogenic signaling pathway genes, but outcomes of both events lead in the overexpression of oncogenic signaling pathways that contribute to the stem-like state of cancer cells. On the basis of recent evidence from population-based, clinical and experimental studies, we hypothesize that factors associated with risk for developing a HM, such as metabolic syndrome and chronic inflammation, trigger epigenetic mechanisms to increase the transcriptional expression of oncogenes and activate oncogenic signaling pathways. Among others, signaling pathways associated with such risk factors include pro-inflammatory nuclear factor κB (NF-κB), and mitogenic, growth, and survival Janus kinase (JAK) intracellular non-receptor tyrosine kinase-triggered pathways, which include signaling pathways such as transducer and activator of transcription (STAT), Ras GTPases/ mitogen-activated protein kinases (MAPKs) /extracellular signal-related kinases (ERKs), phosphatidylinositol 3-kinase (PI3K)/Akt / mammalian target of rapamycin (mTOR), and β-catenin pathways. Recent findings on epigenetic mechanisms at work in HMs and their importance in the etiology and pathogenesis of these diseases are herein summarized and discussed. Furthermore, the role of epigenetic processes in the determination of biological identity, the consequences for interindividual variability in disease clinical profile, and the potential of epigenetic drugs in HMs are also considered.
Lorella Vecchio; Paul Faustin Seke Etet; Maulilio John Kipanyula; Mauro Krampera; Armel Hervé Nwabo Kamdje
Related Documents :
7515918 - Cd31 (pecam-1), cdw32 (fc gamma rii), and anti-hla class i monoclonal antibodies recogn...
8193368 - C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes ...
8925408 - Human neutrophil secondary granule exocytosis is independent of protein kinase activati...
2829728 - Further evidence for the involvement of the phosphorylation of 46k protein(s) in the re...
9569238 - Ligation of the beta2 integrin triggers activation and degranulation of human eosinophils.
15496488 - Decrease in synaptic transmission can reverse the propagation direction of epileptiform...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-16
Journal Detail:
Title:  Biochimica et biophysica acta     Volume:  -     ISSN:  0006-3002     ISO Abbreviation:  Biochim. Biophys. Acta     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217513     Medline TA:  Biochim Biophys Acta     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013. Published by Elsevier B.V.
Laboratory of Cytometry, Institute of Molecular Genetics, CNR, University of Pavia, 27100 Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The motivations, experiences, and perspectives of bone marrow and peripheral blood stem cell donors:...
Next Document:  Recovery of pulmonary structure and exercise capacity by treatment with granulocyte-colony stimulati...